

For the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP) to improve neuromuscular disability and impairment

Strength to move forward

panzyga®

Immune Globulin
Intravenous (Human) - ifas
10% Liquid Preparation

{ pronounced: *pan-zee-guh* }

As part of its commitment to patients with CIDP, Pfizer is proud to offer the **Pfizer Pledge Warranty Program*† for adult patients with CIDP starting PANZYGA**. With this program, eligible patients can get their out-of-pocket drug costs for PANZYGA refunded. See below to learn more.

PfizerPledge™

WARRANTY PROGRAM FOR PANZYGA® (Immune Globulin Intravenous [Human] - ifas)



What does the Pfizer Pledge Warranty Program offer?

- With this program, **eligible patients can be refunded their out-of-pocket drug costs** for up to the first 4 treatments of PANZYGA for chronic inflammatory demyelinating polyneuropathy (CIDP) if the treatment is discontinued by the patient's healthcare provider for clinical reasons
- Per treatment and aggregate maximum refund limits apply. If the patient's commercial insurance and/or other payers paid for all or a portion of the cost of PANZYGA, the plan(s) can be refunded those costs up to the program maximum limits minus any out-of-pocket drug costs paid by the patient



Who is eligible for the Pfizer Pledge Warranty Program?

- The Pfizer Pledge Warranty Program is **available to adult, cash-paying or commercially insured patients** (those with employer-sponsored or private insurance) prescribed PANZYGA for CIDP whose healthcare provider discontinues treatment for clinical reasons before the fifth treatment*
- Patients are not eligible for the program if their PANZYGA was covered, in whole or in part, by Medicare, Medicaid, TRICARE, Veterans Affairs health care, a state prescription drug assistance program, or the Government Health Insurance Plan available in Puerto Rico



How can a patient make a claim?

- For information on the Pfizer Pledge Warranty Program and for access to resources, such as patient claim forms, please visit PanzygaInfo.com



*Not available for residents of Puerto Rico.

†Terms and conditions/eligibility requirements apply. See full terms and conditions at PanzygaInfo.com.

*Single treatments may be given over 1 or more days.

INDICATIONS AND USAGE

PANZYGA (Immune Globulin Intravenous [Human] – ifas) is indicated for the treatment of primary humoral immunodeficiency (PI) in patients 2 years of age and older, chronic immune thrombocytopenia (cITP) in adults and chronic inflammatory demyelinating polyneuropathy (CIDP) in adults.

PANZYGA is a liquid medicine for infusion that contains immunoglobulin G (IgG), which are proteins that help fight infection. It is made from human plasma that is donated by healthy people and contains antibodies. For patients with PI, PANZYGA helps replace the missing antibodies in the body. For patients with cITP, PANZYGA helps the body produce more platelets (the blood cells that help blood clot) to control or prevent bleeding. For patients with CIDP, PANZYGA may help improve mobility and hand strength.

PANZYGA is given into a vein (intravenously) in a hospital, infusion center, doctor's office, or at home by a trained healthcare provider (HCP).


SELECTED SAFETY INFORMATION

WARNING: THROMBOSIS, RENAL DYSFUNCTION, and ACUTE RENAL FAILURE

See full prescribing information for complete **BOXED WARNING**

- **Thrombosis may occur with immune globulin intravenous (IGIV) products, including PANZYGA. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors.**
- **Renal dysfunction, acute renal failure, osmotic nephropathy, and death may occur with the administration of IGIV products in predisposed patients. Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. PANZYGA does not contain sucrose.**
- **For patients at risk of thrombosis, renal dysfunction, or acute renal failure, administer PANZYGA at the minimum infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.**

Please click [here](#) for Full Prescribing Information, including complete **BOXED WARNING**.



For the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP) to improve neuromuscular disability and impairment

Strength to move forward

panzyga®

Immune Globulin
Intravenous (Human) - ifas
10% Liquid Preparation

{ pronounced: *pan-zee-guh* }

SELECTED SAFETY INFORMATION (continued)

Do not use PANZYGA if you:

- Have had a severe allergic reaction to immune globulin or other blood products
- Have a condition called selective (or severe) immunoglobulin A (IgA) deficiency, with antibodies against IgA and a history of hypersensitivity

What should I know before taking PANZYGA?

- PANZYGA can make vaccines (like measles/mumps/rubella or chickenpox vaccines) work less effectively for you. Before you get any vaccines, tell your healthcare provider that you take PANZYGA
- Decreased kidney function and kidney function failure can occur
- Severe headache, drowsiness, fever, painful eye movements, or nausea and vomiting can occur
- Elevated blood pressure can occur particularly in patients who have a history of hypertension (high blood pressure)
- If you are elderly, with heart or kidney problems, discuss with your healthcare provider prior to initiating treatment with PANZYGA
- PANZYGA is made from human blood and therefore may have a risk of transmitting infectious agents, including viruses and, theoretically, the variant Creutzfeldt-Jakob disease (CJD) and CJD agent. The production and manufacturing process reduces this risk, but the risk cannot be eliminated

PANZYGA can cause serious side effects. If any of the following problems occur after starting PANZYGA, stop the infusion immediately and contact your HCP or call emergency services:

- Hives, swelling in the mouth or throat, itching, trouble breathing, wheezing, fainting, or dizziness. These could be signs of a serious allergic reaction
- Bad headache with nausea, vomiting, stiff neck, fever, drowsiness, painful eye movements, and sensitivity to light. These could be signs of irritation and swelling of the lining around your brain
- Reduced urination, sudden weight gain, or swelling in your legs. These could be signs of a kidney problem (decreased kidney function or kidney failure)
- Pain, swelling, warmth, redness, or a lump in your legs or arms. These could be signs of a blood clot, which could happen in the heart, brain, lungs, or elsewhere in the body
- Brown or red urine, swelling, fatigue, fast heart rate, difficulty breathing, or yellow skin or eyes. These could be signs of a liver or blood problem
- Chest pain or trouble breathing, or blue lips or extremities. These could be signs of a serious heart or lung problem
- Fever over 100°F. This could be a sign of an infection
- Headache, fatigue or confusion, vision problem, chest pain, difficulty breathing, irregular heartbeat, or pounding in your chest, neck, or ears. These could be signs of high blood pressure

Ask your HCP whether you should have rescue medications available, such as antihistamines or epinephrine.

What are the possible or reasonably likely side effects for PANZYGA?

The most common side effects that may occur with PANZYGA are:

- Headache
- Nausea
- Fever
- Increased blood pressure
- Dermatitis
- Fatigue
- Abdominal pain
- Dizziness
- Anemia

These are not all the possible side effects. Talk to your HCP about any side effect that bothers you or that does not go away.

Tell your HCP if you are pregnant, or plan to become pregnant, or if you are nursing.



VISIT [PANZYGAINFO.COM](https://panzygainfo.com) TO LEARN MORE

Patients should always ask their doctors for medical advice about adverse events.

You may report an adverse event related to Pfizer products by calling 1-800-438-1985 (US only). If you prefer, you may contact the US Food and Drug Administration (FDA) directly. The FDA has established a reporting service known as MedWatch where healthcare professionals and consumers can report problems they suspect may be associated with the drugs and medical devices they prescribe, dispense, or use. Visit www.fda.gov/MedWatch or call 1-800-FDA-1088.

PANZYGA® is a registered trademark of Octapharma AG.

Please click [here](#) for Full Prescribing Information, including complete **BOXED WARNING**.



octapharma®

Manufactured by Octapharma Pharmazeutika Produktionsges m.b.H.
Distributed by Pfizer Labs, Division of Pfizer Inc.